Colorado's Deion Sanders gives health update, says he's ‘still going through something'
'You know I'm still going through something,' Sanders said in a YouTube video posted by his son Deion Sanders Jr. on Monday. 'I ain't all the way recovered.'
Advertisement
The video showed Sanders and his daughter Shelomi preparing to step into an ice bath. Sanders' quotes were featured in a voiceover added to the video, which also showcased his active lifestyle. It featured Sanders taking a tennis lesson, shooting hoops and walking/running 1.3 miles with Shelomi.
At Big 12 media days nearly two weeks ago, Sanders took the stage in his first public appearance since April and refused to discuss his health issue. He hasn't publicly stated the nature of the problem that's kept him away from campus.
'I'm not here to talk about my health,' Sanders said. 'I'm here to talk about my team.'
Sanders also participated in a coaches roundtable and did two on-air interviews with ESPN at Big 12 media days.
'Average day? I'm looking good,' he said when asked what his day-to-day life looked like during his time away from campus. 'I'm living lovely. God has truly blessed me. Not a care in the world. Not a want or desire in the world.'
Sanders hosted an NFL Draft party at his home for his son Shedeur in April, but hadn't made any public appearances since the Buffaloes' spring game on April 19. Shedeur was projected by some to be a top pick in the draft, but slid to the fifth round, where the Cleveland Browns selected him.
Colorado athletic director Rick George told The Athletic at Big 12 media days that he expected Sanders to return to campus 'in a week or two, probably.' George said the two had been in constant contact since Sanders left campus to deal with his health and recover at his ranch in Canton, Texas, in late April.
A person briefed on the situation told The Athletic that Sanders was in touch with his coaching staff daily but did not appear at Colorado's youth camps during his absence and wasn't on campus during a feverish, five-week recruiting contact period during the summer.
Advertisement
Sanders has a history of blood clot issues, and in 2021, had two toes amputated. In 2023, he had surgery to relieve the clots that kept him from attending Pac-12 media days and spent most of that offseason in pain and limping before reaching his stated goal of running out on the field with his team to begin the season.
Last month, Sanders posted on X that he would update people once he returned to Boulder and was excited to be on campus.
Colorado begins preseason football practice later this month and opens its season against Georgia Tech on Aug. 29.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Wisconsin football offers five-star recruit in the class of 2027
Wisconsin football is setting its sights high in the 2027 recruiting cycle, especially at the tight end position. After offering four-star TE Jaxon Dollar on Tuesday, the program also extended an offer to five-star TE Ahmad Hudson -- one of the nation's top players in the class. 247Sports specifically ranks Hudson as the No. 10 overall player in the 2027 cycle, the No. 1 tight end and the No. 1 player from his home state of Louisiana. Wisconsin is unsurprisingly not alone on the five-star recruit's offer sheet. As of July 23, other programs in pursuit of Hudson include Alabama, Florida State, LSU, Texas A&M, Auburn, Florida, Miami, Nebraska, North Carolina, Ohio State, Ole Miss, Oregon, Texas and USC. 247Sports currently lists Alabama, Baylor, Florida State, in-state LSU and Texas A&M as the early favorites in his recruitment, while On3/Rivals gives LSU (95.9%) a prohibitive early advantage over Nebraska (2%) and others. The 6-foot-6 tight end prospect is also a four-star power forward recruit on the basketball court. Only LSU, Grambling State and Louisiana Tech are listed on his basketball offer sheet. Wisconsin will have significant competition for Hudson's commitment. The program has not landed a five-star recruit since offensive tackle Nolan Rucci during the 2021 cycle. It only has five five-star signees in the online recruiting rankings era: 2001 DT Anttaj Hawthorne, 2003 DE Justin Ostrowski, 2007 OT Josh Oglesby, 2019 OT Logan Brown and Rucci. As noted in our story on Wisconsin's offer to Dollar, another blue-chip tight end in the class, the program is looking to rebuild its tight end room as it transitions back to a pro-style system on offense. Top talent at the position will be paramount to the scheme's success. That reality differs from Phil Longo's air raid scheme, which put more emphasis on speed and talent at wide receiver. Contact/Follow on X (formerly Twitter) and like our page on to follow ongoing coverage of Wisconsin Badgers news, notes and opinion This article originally appeared on Badgers Wire: Wisconsin football recruiting offer 2027 five-star Ahmad Hudson
Yahoo
23 minutes ago
- Yahoo
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas™ Wearable Injector Technology for Biologic Drugs
FRANKLIN LAKES, N.J., July 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announces the first pharma-sponsored combination product clinical trial using the BD Libertas™ Wearable Injector for subcutaneous delivery of complex biologics. The selection of BD Libertas™ Wearable Injector for this pharma-sponsored trial follows successful outcomes from more than 50 BD-conducted pre-clinical and clinical studies, including a device clinical study demonstrating excellent performance with 100% of study participants stating they would likely use the BD Libertas™ Wearable Injector if prescribedi,ii. The pharma-sponsored combination product clinical trial represents a significant advancement in accelerating innovation in drug-device combination products that provide greater flexibility for patients, including potential conversion from infused medications that require patients to travel to a hospital or clinic to more convenient patient care in various settings, including self-injection at home. "This trial demonstrates BD's commitment to helping pharma companies by advancing large-volume injection science, ensuring therapies are accessible and patient friendly by offering more efficient and convenient options for biologics," said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. "BD's enhanced testing capabilities acquired through ZebraSci and the proven capabilities of the BD Libertas™ Wearable Injector technology further position BD as an innovative leader in drug delivery." The BD Libertas™ Wearable Injector is an innovative, prefilled, patient ready-to-use drug delivery systemiii designed to enable delivery of complex biologics via subcutaneous injection. The biologics market is expected to grow to more than $670 billioniv by 2030 and for pharmaceutical companies developing these complex drugs, the BD Libertas™ Wearable Injector offers a customizable, patient-centric solution. The BD Libertas™ Wearable Injector: Supports delivery of high-viscosity biologics (up to 50 centipoise), enabling a wide range of subcutaneous therapies Is offered in 2 to 5 mL and 5 to 10 mL configurations providing flexibility for diverse therapeutic requirements Features a fully mechanical, patient ready-to-use design with a simple "peel, stick and click" mechanism, requiring no end-user filling or assemblyiii BD's ongoing validations of fill-finish and final assembly processes with multiple Contract Manufacturing Organizations (CMOs) enable the company to support pharmaceutical partners from development through commercial-scale production. For more information about how BD Libertas™ Wearable Injector is enabling biologic therapy delivery, visit About BD Libertas™ Wearable InjectorBD Libertas™ Wearable Injector is a product in development; some statements are forward looking and are subject to a variety of risks and uncertainties. BD Libertas™ Wearable Injector is a device component intended for drug-device combination products and not subject to FDA 510(k) clearance or separate EU CE mark certification. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit or connect with us on LinkedIn at X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. Contacts: Media: Investors: Fallon McLoughlin Adam Reiffe BD Corporate Communications BD Investor Relations 201.258.0361 201.847.6927 i Early feasibility clinical study of investigational BD Libertas™ Wearable Injector (WI) evaluated 5ml, non- Newtonian ~8cP subcutaneous placebo injections in 52 healthy adult subjects for functionality, tissue effects, subject tolerability (100mm Visual Analog Scale (VAS)) and acceptability (questionnaires with 5-point Likert or yes /no responses). Tissue effects were measured from WI removal post-injection through 24 hours with calipers (wheals) or graded on a 5-point scale (erythema, bleeding) from 0-none to 4-severe, significant, respectively. Where tissue effects were observed, the majority (>50%) were resolved within 60 minutes and all within 24 hours. Subject pain (100mm VAS) peaked mid-injection (mean 9.1mm, SD 13.4) and rapidly resolved within 30 minutes (mean 0 .4mm, SD 2.6). Subjects found acceptable (Likert agree + strongly agree or yes responses) their peak pain (≥90.2%), injection site appearance (≥92.2% ).ii Woodley, W. D. et al. Clinical Evaluation of an Investigational 5ml Wearable Injector in Healthy Human Subjects. Clin Transl Sci. 2021 May;14(3):859-869. Pharma filled and assemblediv Mordor Intelligence (2025). Biologics Market Size - Industry Report on Share, Growth Trends & Forecasts Analysis (2025 - 2030). View original content to download multimedia: SOURCE BD (Becton, Dickinson and Company) Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
After Mbeumo, is Brentford being too greedy over Yoane Wissa?
Yoane Wissa After seeing his attacking partner, Bryan Mbeumo, head off to Manchester United, Yoane Wissa has made it clear he wants to pack his bags and leave Brentford. But the English club is proving to be a tough negotiator. Last season, Yoane Wissa netted 20 goals in 39 appearances across all competitions. As a result, the Congolese striker is attracting plenty of interest. Newcastle have made a move in recent hours with a €25 million offer. However, the Bees' management immediately turned it down, according to The Athletic. For now, Wissa remains under contract with the club until June 2026. His market value is estimated between €30 and €40 million, and this is not the first time Brentford have rebuffed an approach. Nottingham Forest previously ran into the same stubborn stance from the board earlier in the transfer window. It's clear Brentford are determined to cash in to the fullest on one of the Premier League's most sought-after talents. The English club won't let their striker go unless an offer meets their lofty expectations.
